Form 4: CG Oncology Executive Acquires Stock Options

Joshua F. Patterson, General Counsel and Chief Compliance Officer of CG Oncology, Inc., acquired stock options on October 4, 2024.

Summary

• Joshua F. Patterson, General Counsel and Chief Compliance Officer of CG Oncology, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on October 4, 2024, where Patterson acquired stock options.
• Patterson acquired options to purchase 47,775 shares of CG Oncology's common stock at an exercise price of $36.63.
• The options vest monthly, with 1/48th of the shares vesting each month following October 4, 2024, contingent upon Patterson's continued service to the company.
• Following the reported transaction, Patterson directly owns options for 47,775 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither particularly positive nor negative on its own.

Positives

• The acquisition of stock options by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency regarding the transactions of company insiders. This filing indicates the acquisition of stock options, a common form of executive compensation.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of the shareholders, potentially incentivizing performance that benefits all stakeholders.

Key Dates